Journal of Neurogastroenterology and Motility

The Korean Society of Neurogastroenterology and Motility (대한소화기 기능성질환 운동학회)
권호 표지
DOI QR코드

DOI QR Code

Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test

  • Masaoka, Tatsuhiro (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine) ;
  • Kameyama, Hisako (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine) ;
  • Yamane, Tsuyoshi (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine) ;
  • Yamamoto, Yuta (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine) ;
  • Takeuchi, Hiroya (Department of Surgery, Keio University School of Medicine) ;
  • Suzuki, Hidekazu (Medical Education Center, Keio University School of Medicine) ;
  • Kitagawa, Yuko (Department of Surgery, Keio University School of Medicine) ;
  • Kanai, Takanori (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)
  • Received : 2018.03.03
  • Accepted : 2018.06.17
  • Published : 2018.10.30
⟨ Previous Next ⟩

Abstract

Background/Aims Potassium-competitive acid blockers are expected to be the next generation of drugs for the treatment of diseases caused by gastric acid. In 2015, vonoprazan fumarate, a novel potassium-competitive acid blocker, was approved by the Japanese health insurance system. Since its approval, patients refractory to vonoprazan can be encountered in clinical settings. We designed this study to clarify the pathophysiology of gastroesophageal reflux disease refractory to vonoprazan. Methods In this retrospective study, we involved patients who had refractory symptoms after administration of standard-dose proton pump inhibitors or vonoprazan and underwent diagnostic testing with esophageal high-resolution manometry and 24-hour multichannel intraluminal impedance and pH monitoring while using proton pump inhibitors or vonoprazan. Patients were diagnosed based on the Rome IV criteria for functional gastrointestinal disorders and diagnostic test results. Results Twenty-seven patients were analyzed during this study. Gastric pH ${\geq}4$ was sustained for a longer period of time, and the esophageal acid exposure time and number of acid reflux events were shorter in the vonoprazan group than in the proton pump inhibitor group. The percentage of patients diagnosed with acidic gastroesophageal reflux disease in the vonoprazan group was lower than that in the proton pump inhibitor group. Conclusions Intra-gastric pH and acid reflux were strongly suppressed by 20-mg vonoprazan. When patients with gastroesophageal reflux disease present symptoms after administration of 20-mg vonoprazan, the possibility of pathophysiologies other than acid reflux should be considered.

Keywords

References

  1. Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol 2016;51:751-767. https://doi.org/10.1007/s00535-016-1227-8
  2. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014;63:871-880. https://doi.org/10.1136/gutjnl-2012-304269
  3. Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol 2016;13:281-294. https://doi.org/10.1038/nrgastro.2016.50
  4. Herregods TV, Troelstra M, Weijenborg PW, Bredenoord AJ, Smout AJ. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil 2015;27:1267-1273. https://doi.org/10.1111/nmo.12620
  5. Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil 2014;20:6-16. https://doi.org/10.5056/jnm.2014.20.1.6
  6. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016;65:1439-1446. https://doi.org/10.1136/gutjnl-2015-311304
  7. Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol 2016;111:949-956. https://doi.org/10.1038/ajg.2016.182
  8. Yamashita H, Kanamori A, Kano C, et al. The effects of switching to vonoprazan, a novel potassium-competitive acid blocker, on gastric acidity and reflux patterns in patients with erosive esophagitis refractory to proton pump inhibitors. Digestion 2017;96:52-59. https://doi.org/10.1159/000478255
  9. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-180. https://doi.org/10.1136/gut.45.2.172
  10. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology 2016;150:1380-1392. https://doi.org/10.1053/j.gastro.2016.02.011
  11. Suzuki H, Matsuzaki J, Okada S, Hirata K, Fukuhara S, Hibi T. Validation of the GerdQ questionnaire for the management of gastrooesophageal reflux disease in Japan. United European Gastroenterol J 2013;1:175-183. https://doi.org/10.1177/2050640613485238
  12. Bredenoord AJ, Fox M, Kahrilas PJ, et al. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil 2012;24(suppl 1):57-65. https://doi.org/10.1111/j.1365-2982.2011.01834.x
  13. Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015;27:160-174. https://doi.org/10.1111/nmo.12477
  14. Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil 2017;29:1-15. https://doi.org/10.1111/nmo.13179
  15. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional esophageal disorders. Gastroenterology 2016;150:1368-1379. https://doi.org/10.1053/j.gastro.2016.02.012
  16. Tsuchiya I, Kato Y, Tanida E, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: prospective randomized controlled trial. Dig Endosc 2017;29:576-583. https://doi.org/10.1111/den.12857
  17. Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 2017;95:156-161. https://doi.org/10.1159/000456072
  18. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther 2015;42:719-730. https://doi.org/10.1111/apt.13325
  19. Mitchell DR, Derakhshan MH, Robertson EV, McColl KE. The role of the acid pocket in gastroesophageal reflux disease. J Clin Gastroenterol 2016;50:111-119. https://doi.org/10.1097/MCG.0000000000000439
  20. Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 2009;44:518-534. https://doi.org/10.1007/s00535-009-0047-5
  21. Yamasaki T, Fass R. Reflux hypersensitivity: a new functional esophageal disorder. J Neurogastroenterol Motil 2017;23:495-503. https://doi.org/10.5056/jnm17097
  22. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004;140:518-527. https://doi.org/10.7326/0003-4819-140-7-200404060-00011
  23. Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther 2016;168:12-22. https://doi.org/10.1016/j.pharmthera.2016.08.001
  24. Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol 2016;31:716-726. https://doi.org/10.1111/jgh.13233
  25. Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2007;25:501-510. https://doi.org/10.1111/j.1365-2036.2006.03221.x